MGMT promoter methylation in pediatric high-grade gliomas.

摘要

We read with great interest the recent articles of Buttarelli et al. [1] and Srivastava et al. [2] on MGMT status in pediatric high-grade gliomas. The authors observed MGMT promoter methylation in 7/24 (30%) and 10/20 (50%) of the tumors, respectively. In adults, MGMT promoter methylation is the most promising prognostic marker to predict patients' outcome and it has been observed in the 30-40% of the cases. On the other hand, only sporadic information are available regarding pediatric cases.